Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Centessa Pharmaceuticals (CNTA) Invested Capital (2021 - 2026)

Centessa Pharmaceuticals has reported Invested Capital over the past 5 years, most recently at $637.0 million for Q4 2025.

  • Quarterly Invested Capital rose 24.78% to $637.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $637.0 million through Dec 2025, up 24.78% year-over-year, with the annual reading at $637.0 million for FY2025, 24.78% up from the prior year.
  • Invested Capital was $637.0 million for Q4 2025 at Centessa Pharmaceuticals, up from $411.4 million in the prior quarter.
  • Over five years, Invested Capital peaked at $637.0 million in Q4 2025 and troughed at $215.2 million in Q1 2024.
  • The 5-year median for Invested Capital is $411.4 million (2025), against an average of $392.7 million.
  • Year-over-year, Invested Capital tumbled 38.92% in 2023 and then soared 130.29% in 2025.
  • A 5-year view of Invested Capital shows it stood at $491.6 million in 2021, then plummeted by 31.61% to $336.2 million in 2022, then dropped by 29.72% to $236.2 million in 2023, then skyrocketed by 116.08% to $510.5 million in 2024, then rose by 24.78% to $637.0 million in 2025.
  • Per Business Quant, the three most recent readings for CNTA's Invested Capital are $637.0 million (Q4 2025), $411.4 million (Q3 2025), and $454.5 million (Q2 2025).